MML Investors Services LLC Grows Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

MML Investors Services LLC grew its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 31.4% during the third quarter, Holdings Channel reports. The institutional investor owned 15,454 shares of the company’s stock after acquiring an additional 3,692 shares during the quarter. MML Investors Services LLC’s holdings in Elanco Animal Health were worth $227,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Benjamin F. Edwards & Company Inc. lifted its stake in shares of Elanco Animal Health by 337.7% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock worth $26,000 after buying an additional 1,361 shares during the period. ORG Wealth Partners LLC purchased a new position in Elanco Animal Health in the 3rd quarter worth $29,000. nVerses Capital LLC acquired a new stake in Elanco Animal Health during the 2nd quarter worth about $32,000. AM Squared Ltd acquired a new stake in Elanco Animal Health during the 3rd quarter worth about $34,000. Finally, Quarry LP purchased a new stake in Elanco Animal Health during the 2nd quarter valued at about $40,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Up 1.4 %

Elanco Animal Health stock opened at $12.05 on Friday. Elanco Animal Health Incorporated has a 12 month low of $11.40 and a 12 month high of $18.80. The stock has a market capitalization of $5.96 billion, a PE ratio of 30.13, a price-to-earnings-growth ratio of 2.03 and a beta of 1.41. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The business has a 50 day simple moving average of $12.83 and a 200-day simple moving average of $13.97.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.12 by $0.01. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.04 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm’s revenue was down 3.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.18 EPS. On average, analysts anticipate that Elanco Animal Health Incorporated will post 0.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Barclays raised their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. UBS Group assumed coverage on shares of Elanco Animal Health in a research report on Monday, December 9th. They set a “buy” rating and a $18.00 target price for the company. Leerink Partners began coverage on Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target on the stock. Morgan Stanley cut Elanco Animal Health from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $17.00 to $15.00 in a research report on Thursday, September 19th. Finally, Leerink Partnrs raised shares of Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $16.71.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.